VBC108

VBC108 is a first-in-class bispecific antibody-drug conjugate (ADC) that simultaneously targets Claudin 18.2 (CLDN18.2) and Cadherin 17 (CDH17). Developed by VelaVigo Bio, the agent is designed to treat advanced malignant solid tumors, particularly those of gastrointestinal origin where these two antigens are frequently co-expressed. By dual-targeting CLDN18.2 and CDH17, VBC108 aims to enhance tumor specificity and binding avidity, potentially improving therapeutic efficacy while minimizing off-target toxicity. Upon binding to the target antigens on the cancer cell surface, the ADC is internalized, leading to the intracellular release of a cytotoxic payload that induces cell death. VBC108 is currently being evaluated in a Phase 1/2a clinical trial to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced solid tumors.